Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
The FDA approves Amgen's Lumakras in combination with Vectibix for treating previously treated adults with KRAS G12C-mutated metastatic colorectal cancer.
Pharm Exec14h
FDA Approves Amgen’s Lumakras Plus Vectibix for KRAS G12C-Mutated Metastatic Colorectal Cancer
Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...
Amgen: Likely To Be Rangebound (Rating Downgrade)
Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...
NationofChange21h
Medical fraud and the grand design or extracting profit everywhere at the cost of lives and liberty
Jacobo’s article is well worth reading as it describes a litany of ways major corporations game the system at the cost of lives and billions of dollars. Many of these “opportunities” arise from the ...